使用钆布醇改善腹部对比增强MRA显示:与钆喷酸葡胺的比较
前瞻性、盲法、多中心、个体内比较研究纳入112例患者,比较钆布醇与钆喷酸葡胺(Gd-DTPA)在腹部一站式CE-MRA和CE-MRI中的表现。钆布醇在小血管质量评分上显著优于Gd-DTPA(p=0.036),大血管SNR显著更高(p=0.041);肝、脾、肾实质强化两者无统计学显著差异(p>0.05)。作者认为钆布醇可能更适合腹部一站式CE-MRA和CE-MRI成像。
要点
- 钆布醇小血管质量评分显著优于Gd-DTPA(p=0.036)。
- 钆布醇大血管SNR显著高于Gd-DTPA(p=0.041)。
- 肝、脾、肾实质强化两者无统计学显著差异(p>0.05)。
核心结论
- 钆布醇增强MRA在血管显示上优于Gd-DTPA,在实质器官强化上两者无统计学显著差异,提示钆布醇可能更适合腹部一站式CE-MRA和CE-MRI成像。
研究设计与样本
- 前瞻性、盲法、多中心、个体内比较研究,经机构审查委员会批准,共纳入112例患者,所有患者均接受钆布醇和Gd-DTPA增强MRA及MRI检查。
关键影像表现/征象
- 大血管质量分析:钆布醇18.38±1.51 vs Gd-DTPA 17.87±1.84。
- 小血管质量分析:钆布醇6.76±1.58 vs Gd-DTPA 6.09±1.55,钆布醇显著优于Gd-DTPA(p=0.036)。
- 大血管SNR定量分析:钆布醇948.156±349.731 vs Gd-DTPA 838.925±248.197,钆布醇显著更高(p=0.041)。
- 肝、脾、肾组织强化在钆布醇与Gd-DTPA增强成像间无统计学显著差异(p>0.05)。
诊断标准与关键数值
- 血管定性分析采用三点量表评分。
- 血管定量分析采用信噪比(SNR)。
- 统计学比较采用Wilcoxon配对符号秩检验。
临床应用与阅片要点
- 作者认为钆布醇可能更适合腹部一站式CE-MRA和CE-MRI成像,因其可改善MRA图像中的血管显示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To qualitatively and quantitatively compare gadobutrol with gadopentetate dimeglumine (Gd-DTPA) in abdominal contrast-enhanced magnetic resonance angiography (CE-MRA) and contrast-enhanced magnetic resonance imaging (CE-MRI) during one-stop imaging.
MATERIALS AND METHODS: This prospective, blinded, multicentre, intra-individual comparison study was approved by the institutional review board. All patients underwent gadobutrol- and Gd-DTPA-enhanced MRA and MRI. Qualitative analysis for vessels was performed using a three-point scale while quantity analysis was performed by signal-to-noise ratio (SNR). Visceral organs enhancements were also analysed. A Wilcoxon matched-pair signed-rank test was used to evaluate the quality and quantity results.
RESULTS: One hundred and twelve patients were enrolled. Quality analyses results for large vessels and small vessels of gadobutrol and Gd-DTPA were 18.38±1.51 and 6.76±1.58 and 17.87±1.84 and 6.09±1.55, respectively. Wilcoxon signed-rank tests revealed gadobutrol was significantly superior to Gd-DTPA (p=0.036) for small vessels. For large vessel quantity analysis, gadobutrol demonstrated significantly higher signal-to-noise ratios (SNR; p=0.041) than Gd-DTPA, with mean values of 948.156±349.731 and 838.925±248.197. There was no statistically significant in enhancement of liver, spleen, and renal tissue during gadobutrol- and Gd-DTPA-enhanced imaging (p>0.05). One patient reported an adverse event. Dizziness and vomiting occurred after injection of Gd-DTPA.
CONCLUSIONS: The present study demonstrates gadobutrol-enhanced MRA was superior to that of Gd-DTPA without statistical significance in visceral organ enhancement. It indicates gadobutrol may be more suitable for abdominal one-stop imaging for CE-MRA and CE-MRI by improving depiction of vessels in MRA images.
引用
- Liu X, Zhang W, Li Z, et al. Improved display of abdominal contrast-enhanced MRA using gadobutrol: comparison with Gd-DTPA. Clin Radiol. 2019. PMID: 31551147. doi:10.1016/j.crad.2019.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。